Sourcing Guide

How to Vet a Supplement Contract Manufacturer: A 10-Point Checklist

By Kevin Zeng, OEM Specialist | Huake Biotechnology · Updated September 2026 · 8 min read

Most brand owners choose a supplement manufacturer based on two things: a good sample and a good price. Those are the right starting points — and the wrong finish line. The sample proves the factory can make one batch. The contract, the audit trail and the quality system prove they can make yours, batch after batch, for years.

Outsourcing is the industry norm: roughly 55% of US supplement production is contracted out to contract manufacturers, a share projected to reach about 60% by 2026 (Nutrition Business Journal). Yet the FDA inspects only about 5% of registered dietary supplement facilities each year, and in FY2023 roughly 5% of inspections were classified as Official Action Indicated — the most serious outcome (SupplySide). The practical meaning is direct: your own due diligence is an earlier, more controllable quality defense than any official inspection schedule. It is the cheapest insurance your brand will ever buy.

~55%
Of US supplement production is contracted out
Nutrition Business Journal
~5%
Of registered supplement facilities inspected by FDA each year
FDA ODSP / SupplySide
~5%
Of FY2023 inspections rated Official Action Indicated
SupplySide
66
Identity-testing violations observed in 2024, up from ~0 in 2023
FDA inspection data

Why the Checklist Exists

FDA warning letters to supplement manufacturers follow a consistent pattern: missing product specifications, inadequate raw material testing, incomplete master manufacturing records, and weak controls over foreign objects and contamination. These are not exotic failures — they are the most common findings in agency inspections. Most of them are invisible in a sample bottle. That is why you audit the system, not the sample.

The checklist below is built from 21 CFR Part 111 requirements, third-party audit practice, and the contract clauses that cause the most disputes between brands and factories. Work through it before you sign, and keep the answers on file. A factory that answers all ten points openly is a partner you can build on.

The 10-Point Checklist

1. Certification Scope and Validity

Ask for current GMP certification, ISO and HACCP certificates — then read the scope. A GMP certificate that covers only soft chews does not cover your gummies. Confirm the issuing body, the audit date, and whether the certificate is still valid. Ask whether the factory has received any FDA warning letters or Form 483 observations in the past three years, and ask to see the corrective action summary. A transparent partner will share certificates and test reports with serious prospects during the evaluation stage — secrecy about qualifications is itself a warning sign.

2. Laboratory Capability and COA Completeness

Request a sample batch COA and check what is actually tested: identity, purity, strength, composition, heavy metals, and microbiology. A complete batch COA lists the real measured results for every batch — identity, purity, active-ingredient content, heavy-metal limits and microbial results — not just the theoretical values that match the label formula. A COA that only lists the label formula is not a COA. Ask whether testing is done in-house or by third-party labs, and whether you can see the raw test reports for your batch, not just a summary sheet.

3. Ingredient Sourcing and Traceability

Ask where the key raw materials come from and whether suppliers are qualified and re-audited. Request the raw material specifications and certificates for your active ingredients. Confirm whether the factory tests incoming materials or trusts supplier paperwork — in FDA inspections, inadequate raw material testing is one of the most common findings.

4. Formula Ownership and Exclusivity

For private-label and custom work, get formula ownership in writing. Confirm whether the formula is exclusive to you or available to other brands, and whether the factory may substitute ingredients or sources without your approval. Raw material ownership clauses and partial IP claims are common contract flashpoints — resolve them before you pay for development.

5. True MOQ and Total Cost

Ask for the real MOQ for your exact configuration: stock formula, light customization, and full custom. Confirm what the unit price includes and what it does not — packaging, labels, tooling, stability studies, and testing can all be quoted separately. A low MOQ is only useful if the total first-run cost fits your budget.

6. Lead Times and Capacity

Get sampling, production, and shipping lead times in writing. Ask how capacity looks during peak seasons and whether your order could slip behind larger customers. Confirm how production is scheduled, and whether your reorder gets priority after the first run. Vague lead times and no written commitments are a red flag.

7. Compliance and Label Support

Your manufacturer should know the rules for your target market: US structure/function claim rules and disclaimers, EU EFSA-approved claims, and labeling requirements for your destination country. Ask whether they review your label for compliance before printing, and whether they supply the export documents you need. A factory that only says "you handle compliance" is shifting risk onto you.

8. Documentation and Batch Records

Request the quality manual, SOP index, master manufacturing records, and a recent batch record for a product similar to yours. Check whether batch records capture blend times, process temperatures, lot codes, and yield reconciliation. Incomplete records are one of the most common FDA findings — and they make recalls and complaint investigations nearly impossible.

9. Communication and Project Management

Confirm who your project contact is, how quickly they respond, and whether you get proactive updates on sampling, production, and shipment. For overseas brands, time-zone overlap and a documented communication channel matter as much as the factory floor. Ask for a sample project timeline so you can judge their planning quality.

10. Site Access and Audit Transparency

Good factories welcome questions and visits. Ask whether you can visit the facility, do a virtual tour, or commission a third-party audit, and whether they will share the summary report. Refusal to allow any form of audit, or reluctance to share certificates and batch records, is the single strongest red flag in this checklist.

Red Flags That Should End the Conversation

If a factory answers every checklist point openly — including sharing certificates, sample COAs and batch documentation — that openness is itself the strongest signal you have found a reliable partner.

The Huake Take

We wrote this checklist the way we run our own facility: current GMP, ISO and HACCP-compliant production; batch COAs that list real test results; qualified raw material sourcing with incoming-material controls; clear MOQ, lead time and payment terms in writing; label and export compliance support for the markets we ship to; and open books — request a sample COA or a virtual facility tour any time. None of the red flags above apply to how we work, and we will answer your checklist questions during the evaluation stage. Our low-MOQ private-label program for dietary and pet supplements is designed for brands that want to start small and scale with one partner.

Put the Checklist to Work

Send us your product idea and target market, and we will answer all ten checklist points together with a free, no-obligation quote within 24 hours — including MOQ, sample COA, lead time and total first-run cost. Our written answers to the checklist can serve as your internal supplier-approval record. No hidden fees, no surprise minimums.

Email: sales@huakebiotech.com · WhatsApp: +86 138 0889 2995 · www.huakebiotech.com

Sources

  1. Nutrition Business Journal (via Pacific Securities research note): roughly 55% of US supplement production contracted out; share projected near 60% by 2026.
  2. FDA Office of Dietary Supplement Programs (ODSP) data, cited by SupplySide: FDA inspects roughly 5% of the estimated 10,000–12,000 registered supplement facilities per year.
  3. SupplySide (Jan 2024): of FDA supplement cGMP inspections in FY2023, ~5% classified as Official Action Indicated (OAI); ~10% of foreign-facility inspections.
  4. FDA 21 CFR Part 111 & FY2023–2024 inspection data: most common findings include missing product specifications, inadequate raw material testing, incomplete master manufacturing/batch records, and weak contamination controls.
  5. Industry audit guidance (Blue Ocean Regulatory, Nutra Aeon, CSK Biotech): red flags include reluctance to share certificates or audits, lack of lab testing capability, missing batch records, and refusal to permit third-party audits.